Platform Specialty Products Corp Form 424B3 November 06, 2014

> Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration Statement No. 333-196235

> > November 6, 2014

### PROSPECTUS SUPPLEMENT NO. 12

#### 14,825,000 Shares of Common Stock

This prospectus supplement amends our prospectus dated June 19, 2014, as supplemented on July 15, 2014, July 21, 2014, August 6, 2014, August 8, 2014, September 26, 2014, October 1, 2014, October 8, 2014, October 21, 2014, October 30, 2014 and November 4, 2014 (the "Prospectus") to allow the selling stockholders named in the Prospectus (the "Selling Stockholders") to resell, from time to time, up to 14,825,000 shares of our common stock. The shares of our common stock covered by the Prospectus (the "Shares") were issued by us to the selling stockholders in a private placement on May 20, 2014, as more fully described in the Prospectus.

This prospectus supplement is being filed to include the information set forth in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on November 6, 2014, which is set forth below. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement.

Our shares of common stock are listed on the New York Stock Exchange (the "NYSE") under the ticker symbol "PAH." The closing sale price on the NYSE for our shares of common stock on November 5, 2014 was \$25.84 per share.

We are an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012.

Investing in our common stock involves risks. You should carefully consider the risks that we have described in "Risk Factors" beginning on page 6 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus, before investing in the Shares.

Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

You should rely only on the information contained in the Prospectus, this prospectus supplement or any future prospectus supplement or amendment. Neither we nor the selling stockholders have authorized anyone to provide you with different information. The selling stockholders are not making an offer of their Shares in any state where such offer is not permitted.

The date of this Prospectus Supplement No. 12 is November 6, 2014.

Edgar Filing: Platform Specialty Products Corp - Form 424B3

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

#### FORM 8-K

#### CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 3, 2014

Platform Specialty Products Corporation (Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-36272 (Commission File Number) 37-1744899 (I.R.S. Employer Identification No.)

5200 Blue Lagoon Drive Suite 855 Miami, FL (Address of Principal Executive Offices)

33126 (Zip Code)

Registrant's telephone number, including area code: (203) 575-5850

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: Platform Specialty Products Corp - Form 424B3

Item 1.01. Entry into a Material Definitive Agreement.

As previously announced, on November 3, 2014, Platform Specialty Products Corporation ("Platform") completed the acquisition of the agrochemicals business, Chemtura AgroSolutions ("CAS"), of Chemtura Corporation, a Delaware corporation ("Chemtura"), pursuant to the Stock and Asset Purchase Agreement, dated April 16, 2014, between Platform and Chemtura (the "CAS Acquisition"). In connection with the consummation of the CAS Acquisition, on November 3, 2014, Platform and MacDermid Transactional Services Company, a Delaware corporation and subsidiary of Platform ("MTSC"), entered into six supply agreements (the "Supply Agreements") with Chemtura and certain subsidiaries of Chemtura (collectively, the "Chemtura Parties").

Pursuant to the terms of the Supply Agreements, the Chemtura Parties have agreed to supply certain products to MTSC, on an exclusive basis, for a period of at least four years following the consummation of the CAS Acquisition (subject to earlier termination in the event of uncured breach or insolvency of a party). The Supply Agreements also contain customary warranties, disclaimers, limitations of liability, confidentiality and other obligations of the parties.

The foregoing summary of the Supply Agreements does not purport to be complete and is qualified in its entirety by reference to the form of Supply Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 3.02 Unregistered Sales of Equity Securities.

On November 6, 2014, following receipt of stockholder approval at a special meeting of Platform stockholders held on November 6, 2014 (the "Special Meeting"), Platform completed the previously announced sale of 9,404,064 shares of Platform's common stock (the "Shares") to certain funds managed by Pershing Square Capital Management, L.P. ("Pershing Square") for an aggregate purchase price of \$240.6 million. In connection therewith, Platform entered into a registration rights agreement with Pershing Square pursuant to which Platform agreed to (i) file a resale registration statement with the SEC covering the resale of the Shares, as promptly as practicable following the Special Meeting and, in any event, within ten (10) business days following the filing of Platform's annual report on Form 10-K for the year ended December 31, 2014 (the "Filing Date"); provided, however, that (x) in no event Platform will be obligated to make the initial filing of the resale registration statement until such time as Platform is able to comply with the financial statement requirements under Regulation S-X of the SEC's rules and regulations, and (y) Platform may comply with the foregoing obligations by amending an existing resale registration statement to include the Shares; (ii) use commercially reasonable efforts, subject to receipt of necessary information from all the purchasers of the Shares, to cause the SEC to declare the resale registration statement effective by the earlier of (a) three business days after the SEC has advised Platform that the resale registration statement has not been selected for review by the SEC, (b) three business days after the SEC has advised Platform that it has no further comments to the resale registration statement, or (c) 90 days after the Filing Date.

The foregoing summary of the registration rights agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement. A copy of the form of such registration rights agreement was filed as Exhibit 10.3 to the Current Report on Form 8-K filed by Platform on October 8, 2014, and is incorporated herein by reference.

The Shares were offered and sold in a private placement to certain eligible investors pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The Shares have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration under or an applicable exemption from such registration requirements. This Current Report on Form 8-K does not constitute an offer to sell, or a solicitation of an offer to purchase, the Shares or Additional Shares in any jurisdiction in which such offer or solicitation would be unlawful.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On November 6, 2014, Platform held the Special Meeting. The proposal submitted to a stockholder vote at the Special Meeting is described in detail in the definitive proxy statement filed by Platform with the Securities and Exchange Commission on October 17, 2014. Stockholders present in person or by proxy representing 126,940,292 shares of Platform's common stock (or 82.38% of the outstanding shares of Platform's common stock as of October 15, 2014, the record date for the Special Meeting) voted as set forth below:

Proposal: Platform's stockholders approved the issuance to Pershing Square of 9,404,064 shares of Platform's common stock, which represented an amount in excess of 1% of the number of shares of Platform's common stock outstanding on October 3, 2014, at a purchase price of \$25.59 per share, as set forth below:

Voted For 126,819,44	Voted Against 6 53,159	Abstained 67,687	Broker Non-Votes 	
Item 9.01 Financial Statements and Exhibits.				
(d) Exhibits				
Exhibit NumberExhibit Title10.1Form of supply agreement between Platform and Chemtura Corporation.10.2Form of registration rights agreement between Platform and Pershing Square (filed as Exhibit 10.)to Platform's Current Penert on Form % K on filed on October % 2014, and incorporated barring here.				
	to Platform's Current Report on Form 8-K, as filed on October 8, 2014, and incorporated herein b reference).			

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## PLATFORM SPECIALTY PRODUCTS CORPORATION

November 6, 2014

By:/s/ Frank J. MonteiroName:Frank J. MonteiroTitle:Senior Vice President and Chief Financial Officer

# Exhibit Index

Exhibit Number	Exhibit Title		
10.1	Form of supply agreement between Platform and Chemtura Corporation.		
10.2	Form of registration rights agreement between Platform and Pershing Square (filed as Exhibit 10.3		
	to Platform's Current Report on Form 8-K, as filed on October 8, 2014, and incorporated herein by		
	reference).		